A new trading day began on Tuesday, with 10x Genomics Inc (NASDAQ: TXG) stock price down -1.50% from the previous day of trading, before settling in for the closing price of $15.37. TXG’s price has ranged from $14.02 to $57.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 35.76%. Meanwhile, its annual earnings per share averaged 36.71%. With a float of $99.61 million, this company’s outstanding shares have now reached $105.04 million.
Let’s determine the extent of company efficiency that accounts for 1259 employees. In terms of profitability, gross margin is 63.96%, operating margin of -36.65%, and the pretax margin is -36.92%.
10x Genomics Inc (TXG) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Health Information Services Industry. The insider ownership of 10x Genomics Inc is 17.33%, while institutional ownership is 81.63%. The most recent insider transaction that took place on Aug 22 ’24, was worth 152,053. In this transaction Chief Executive Officer of this company sold 6,749 shares at a rate of $22.53, taking the stock ownership to the 882,467 shares. Before that another transaction happened on Aug 22 ’24, when Company’s See Remarks sold 4,351 for $22.53, making the entire transaction worth $98,027. This insider now owns 345,704 shares in total.
10x Genomics Inc (TXG) Earnings and Forecasts
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.79 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.71% per share during the next fiscal year.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Here are 10x Genomics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.02, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
Looking closely at 10x Genomics Inc (NASDAQ: TXG), its last 5-days average volume was 1.9 million, which is a jump from its year-to-date volume of 1.7 million. As of the previous 9 days, the stock’s Stochastic %D was 27.02%. Additionally, its Average True Range was 1.23.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 10.43%, which indicates a significant decrease from 16.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 122.47% in the past 14 days, which was higher than the 85.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.84, while its 200-day Moving Average is $28.64. However, in the short run, 10x Genomics Inc’s stock first resistance to watch stands at $15.45. Second resistance stands at $15.77. The third major resistance level sits at $16.03. If the price goes on to break the first support level at $14.88, it is likely to go to the next support level at $14.62. Should the price break the second support level, the third support level stands at $14.31.
10x Genomics Inc (NASDAQ: TXG) Key Stats
With a market capitalization of 1.82 billion, the company has a total of 119,167K Shares Outstanding. Currently, annual sales are 618,730 K while annual income is -255,100 K. The company’s previous quarter sales were 153,100 K while its latest quarter income was -37,900 K.
